Equillium to Host Business Update Call on October 1, 2019
Time: 4:30 PM Eastern Time |
Dial In: (866) 930-5156 (International callers please use (409) 937-8975) and use reservation code: 7080957. Please dial in 5 to 10 minutes prior to scheduled start time.
Live Webcast: www.equilliumbio.com, accessed through the “Investors” section of the Company's website. The webcast will be archived and available on Equillium’s website for 30 days following the call. Please logon approximately 5 to 10 minutes prior to scheduled start time to download and install any audio software if needed.
If you are unable to participate, the audio webcast of the conference call will be available for replay on Equillium’s website for 30 days following the call.
Equillium’s initial product candidate, itolizumab (EQ001), is a clinical-stage, first-in-class monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. CD6 plays a central role in modulating the activity and trafficking of T cells that drive a number of immuno-inflammatory diseases. Itolizumab is a clinically-validated therapeutic that has demonstrated a favorable safety and tolerability profile.